CD38 GEAR NK cell anti-CD38 mAb companion diagnostic - Coeptis Therapeutics
Latest Information Update: 03 Aug 2023
At a glance
- Originator Coeptis Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Aug 2023 Coeptis Therapeutics submits 513(g) request to the US FDA for CD38 GEAR NK cell anti-CD38 mAb companion diagnostic
- 29 Mar 2023 Coeptis Therapeutics exercises its option to acquire CD38-GEAR-NK cell therapy and CD38 diagnostic test from VyGen-Bio
- 29 Mar 2023 Early research in Cancer (Diagnosis) in USA (Parenteral)